Anti-Rheumatics Market - Global Forecast 2026-2032

The anti-rheumatics market is undergoing significant transformation as advances in science, payer priorities, and patient access requirements redefine strategies across the therapeutic landscape. This report delivers actionable insights for senior decision-makers navigating evolving dynamics in anti-rheumatic care.

Market Snapshot: Anti-Rheumatics Market Size and Growth

The anti-rheumatics market grew from USD 101.95 billion in 2025 to USD 107.71 billion in 2026, with a compound annual growth rate (CAGR) of 5.89% forecasted to reach USD 152.28 billion by 2032. Key factors driving this expansion include clinical innovation, regulatory evolution, and increasing emphasis on outcomes, safety, and access for patients with autoimmune and inflammatory conditions.

Scope & Segmentation

Drug Classes: Corticosteroids, nonsteroidal anti-inflammatory drugs, uric acid drugs, and disease-modifying anti-rheumatic drugs (DMARDs). The DMARD segment encompasses biologic, conventional, and targeted synthetic subtypes.
Therapy Types: Biologics, biosimilars, targeted synthetic therapies, and small-molecule generics.
Routes of Administration: Oral, injectable, and topical therapies, supporting a range of clinical and patient-centric use cases.
Disease Indications: Covers diverse conditions including rheumatoid arthritis, gout, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, osteoporosis, polymyalgia rheumatica, systemic lupus erythematosus, systemic sclerosis, tendinitis, and Sjögren's syndrome.
Distribution Channels: Hospital pharmacies, retail pharmacies, and online pharmacies, each serving different patient populations and influencing access strategies.
Regional Coverage: Americas; Europe, Middle East & Africa; Asia-Pacific. Each region features differentiated regulatory, reimbursement, and distribution frameworks.

Key Takeaways: Strategic Insights for Senior Leaders

Scientific progress in molecular biology and immunology continues to fuel the development of new therapies with unique mechanisms of action.
Payer and health system demands for safety, outcomes evidence, and total care cost push manufacturers to adapt commercialization and market access approaches.
Biosimilars are intensifying competitive pressures, requiring innovators to differentiate through robust, real-world evidence and targeted value demonstration.
Digital health adoption—including remote monitoring and telemedicine—drives more personalized patient engagement and impacts therapeutic adherence.
Collaborative partnerships among industry, payers, and providers are critical to translating innovation into accessible, sustainable care.
Agile supply chain planning and resilient operational strategies are increasingly important due to external pressures such as trade policy shifts and regional regulatory updates.

Tariff Impact: Navigating Trade Policy Shifts

Changes in 2025 tariff structures heightened supply chain complexity for anti-rheumatic manufacturers and distributors. Companies responded by diversifying suppliers, nearshoring production, and strengthening inventory management to cushion against volatility. These adaptations influenced pricing and contract negotiations, prompting closer alignment with payers on rebate and risk-sharing models. Some policy interventions offered temporary relief, but long-term supply chain resilience and localized manufacturing are now central to commercial strategy.

Methodology & Data Sources

This report draws on structured interviews with clinical, commercial, and payer stakeholders, complemented by secondary analysis of peer-reviewed literature, regulatory documents, and public company disclosures. Triangulation of primary and secondary sources ensured validation across themes, including adoption trends, strategic responses, and operational adaptations.

Why This Report Matters

Enables leaders to benchmark commercial and access strategies against shifting payer and regulatory requirements across regions and product segments.
Supports evidence-based investment in innovation, digital integration, and patient support to maximize long-term value and competitive positioning.
Provides a holistic view of global anti-rheumatics market trends, operational risks, and future-proofing strategies essential for sustainable growth.

Conclusion

Aligning scientific advancement with tailored commercialization, robust operations, and strategic payer engagement is essential to succeed in anti-rheumatic care. Stakeholders who prioritize segmentation, digital care, and market-specific strategies will be well-placed to deliver clinical and commercial value.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Rheumatics Market, by Drug Class

8.1. Corticosteroids
8.2. Disease Modifying Anti-rheumatics Drugs
8.2.1. Biologic DMARDs
8.2.1.1. B-cell Inhibitors
8.2.1.2. Interleukin Inhibitors
8.2.1.3. T-cell Co-stimulation Modulators
8.2.1.4. Tumor Necrosis Factor (TNF) Inhibitors
8.2.2. Conventional DMARDs
8.2.3. Targeted Synthetic DMARDs
8.3. Nonsteroidal Anti-inflammatory Drugs
8.4. Uric Acid Drugs

9. Anti-Rheumatics Market, by Route Of Administration

9.1. Injectable
9.2. Oral
9.3. Topical

10. Anti-Rheumatics Market, by Type

10.1. Over-the-Counter Drugs
10.2. Prescription-Based Drugs

11. Anti-Rheumatics Market, by Disease Type

11.1. Ankylosing Spondylitis
11.2. Bursitis
11.3. Gout
11.4. Juvenile Idiopathic Arthritis
11.5. Osteoarthritis
11.6. Osteoporosis
11.7. Polymyalgia Rheumatica
11.8. Psoriatic Arthritis
11.9. Rheumatoid Arthritis
11.10. Sjögren's Syndrome
11.11. Systemic Lupus Erythematosus
11.12. Systemic Sclerosis/Scleroderma
11.13. Tendinitis

12. Anti-Rheumatics Market, by Distribution Channel

12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies

13. Anti-Rheumatics Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Anti-Rheumatics Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Anti-Rheumatics Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Anti-Rheumatics Market
17. China Anti-Rheumatics Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Alvotech
18.7. Amgen Inc.
18.8. ANI Pharmaceuticals, Inc.
18.9. AstraZeneca PLC
18.10. Bayer AG
18.11. Biogen Inc.
18.12. Bristol-Myers Squibb Company
18.13. C. H. Boehringer Sohn AG & Co. KG
18.14. DeepCure
18.15. Eisai Co., Ltd.
18.16. Eli Lilly and Company
18.17. F. Hoffmann-La Roche Ltd.
18.18. Fresenius Kabi AG
18.19. Galapagos NV
18.20. Gilead Sciences, Inc.
18.21. GlaxoSmithKline PLC
18.22. ILTOO Pharma SAS
18.23. Johnson & Johnson Services Inc.
18.24. medac GmbH
18.25. Merck & Co., Inc.
18.26. Novartis AG
18.27. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
18.28. Pfizer, Inc.
18.29. Regeneron Pharmaceuticals, Inc.
18.30. Sanofi SA
18.31. Takeda Pharmaceutical Company Limited
18.32. Teva Pharmaceutical Industries Ltd.
18.33. UCB S.A.
18.34. Vertex Pharmaceuticals Incorporated

List of Figures

FIGURE 1. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJÖGREN'S SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJÖGREN'S SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJÖGREN'S SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 141. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 142. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 145. EUROPE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 156. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 157. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 158. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 160. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 161. AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 171. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 173. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 174. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 175. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 177. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 178. ASEAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. GCC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. GCC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 181. GCC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 182. GCC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 183. GCC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. GCC ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 185. GCC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 186. GCC ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. BRICS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. BRICS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. BRICS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 198. BRICS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 199. BRICS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. BRICS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 201. BRICS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 202. BRICS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. G7 ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. G7 ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 205. G7 ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 206. G7 ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 207. G7 ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. G7 ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 209. G7 ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 210. G7 ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. NATO ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 212. NATO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 213. NATO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 214. NATO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 215. NATO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. NATO ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 217. NATO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 218. NATO ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. CHINA ANTI-RHEUMATICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 229. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 230. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2032 (USD MILLION)
TABLE 231. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2032 (USD MILLION)
TABLE 232. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. CHINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 234. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 235. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Anti-Rheumatics market report include:

AbbVie Inc.
Alvotech
Amgen Inc.
ANI Pharmaceuticals, Inc.
AstraZeneca PLC
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
C. H. Boehringer Sohn AG & Co. KG
DeepCure
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Fresenius Kabi AG
Galapagos NV
Gilead Sciences, Inc.
GlaxoSmithKline PLC
ILTOO Pharma SAS
Johnson & Johnson Services Inc.
medac GmbH
Merck & Co., Inc.
Novartis AG
Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
Pfizer, Inc.
Regeneron Pharmaceuticals, Inc.
Sanofi SA
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Vertex Pharmaceuticals Incorporated

Table Information

Report Attribute	Details
No. of Pages	194
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 107.71 Billion
Forecasted Market Value ( USD ) by 2032	$ 152.28 Billion
Compound Annual Growth Rate	5.8%
Regions Covered	Global
No. of Companies Mentioned	31

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot: Anti-Rheumatics Market Size and Growth

Scope & Segmentation

Key Takeaways: Strategic Insights for Senior Leaders

Tariff Impact: Navigating Trade Policy Shifts

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2025-2033

Anti-Inflammatory Therapeutics: Market Share, and Growth Analysis by Product Type (Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Disease Modifying Anti-rheumatic Drugs), Application, End User, Technology

Psoriatic Arthritis Market Report and Forecast 2025-2034

Psoriatic Arthritis Therapeutics - Global Strategic Business Report

Rheumatoid Arthritis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)